<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985268</url>
  </required_header>
  <id_info>
    <org_study_id>MHICC-2016-001</org_study_id>
    <nct_id>NCT02985268</nct_id>
  </id_info>
  <brief_title>Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF</brief_title>
  <acronym>EVOLVE-HF</acronym>
  <official_title>Evaluation of Outcomes of Cardiac Resynchronization Therapy and MitraClip for the Treatment of Low Ejection Fraction and Functional Mitral Valve Regurgitation in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the optimal treatment strategy for heart failure patients and moderate-to-severe&#xD;
      (3+) or severe (4+) mitral regurgitation with a class IIa recommendation for CRT is&#xD;
      uncertain.Whether these patents should also be treated for functional mitral regurgitation or&#xD;
      with CRT also remains unclear. We therefore propose a randomized 2x2 factorial design in this&#xD;
      patient population to understand the the impact of both CRT and transcatheter mitral valve&#xD;
      repair with the MitraClip on their functional status and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in distance walked on a six-minute walk test (6MWT)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiographic endpoints</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Mitral regurgitation severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiographic endpoints</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Indexed left ventricular end-systolic volume (LVESVi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiographic endpoints</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Left ventricular ejection fraction (LVEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessment scores</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessment scores</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Euro Quality of Life Questionnaire (EQ5DL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Re-hospitalizations for decompensated heart failure</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Wearable activity/heart rate sensor (Fitbit Charge 2)</measure>
    <time_frame>12 months</time_frame>
    <description>Assessments obtained from the wearable activity/heart rate sensor:&#xD;
Mean daily heart rate&#xD;
Daily heart rate range calculated as the difference between min and max heart rate&#xD;
number of daily steps&#xD;
number of daily hours of sleep</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>Time to major adverse cardiac events:&#xD;
Cardiovascular death&#xD;
All -cause mortality&#xD;
non-fatal Myocardial Infarction&#xD;
fatal and non-fatal stroke&#xD;
rehospitalization for decompensated heart failure</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Functional Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MitraClip/Optimal Medical Therapy (OMT) and CRT ON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MitraClip/OMT and CRT OFF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT and CRT ON</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to be implanted with only the CRT-D and will receive optimal medical therapy.&#xD;
CRT-D will be programmed to ON</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT and CRT OFF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to be implanted with only the CRT-D and will receive optimal medical therapy.&#xD;
CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip</intervention_name>
    <description>The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.</description>
    <arm_group_label>MitraClip/OMT and CRT OFF</arm_group_label>
    <arm_group_label>MitraClip/Optimal Medical Therapy (OMT) and CRT ON</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker</description>
    <arm_group_label>MitraClip/OMT and CRT OFF</arm_group_label>
    <arm_group_label>MitraClip/Optimal Medical Therapy (OMT) and CRT ON</arm_group_label>
    <arm_group_label>OMT and CRT OFF</arm_group_label>
    <arm_group_label>OMT and CRT ON</arm_group_label>
    <other_name>OMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-D</intervention_name>
    <description>Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.</description>
    <arm_group_label>MitraClip/OMT and CRT OFF</arm_group_label>
    <arm_group_label>MitraClip/Optimal Medical Therapy (OMT) and CRT ON</arm_group_label>
    <arm_group_label>OMT and CRT OFF</arm_group_label>
    <arm_group_label>OMT and CRT ON</arm_group_label>
    <other_name>Cardiac Resynchronization Therapy and Defibrillator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic moderate-to-severe (3+) or severe (4+) functional mitral regurgitation due&#xD;
             to cardiomyopathy of either ischemic or non-ischemic etiology as determined by&#xD;
             transthoracic echocardiogram (TTE), and confirmed by the Echocardiography Core Lab&#xD;
             (ECL);&#xD;
&#xD;
          2. Symptomatic heart failure as defined by New York Heart Association (NYHA) class II,&#xD;
             III or ambulatory IV;&#xD;
&#xD;
          3. Treatment and compliance with optimal medical therapy for heart failure for at least&#xD;
             30 days; Optimal medical therapy is defined by: Maximum tolerated beta-blocker,&#xD;
             angiotensin converting enzyme inhibitor (ACE) or angiotensin receptor blocker (ARB),&#xD;
             and aldosterone antagonist (as per the ACCF/AHA Guidelines as judged by the HF&#xD;
             specialist investigator on site and confirmed by the Clinical Eligibility Committee).&#xD;
&#xD;
          4. Left ventricular ejection fraction ≤ 35%, as assessed by any one of the following&#xD;
             methods: echocardiography, contrast left ventriculography, gated blood pool scan or&#xD;
             cardiac magnetic resonance imaging (MRI);&#xD;
&#xD;
          5. Class IIa indication for cardiac resynchronization therapy:&#xD;
&#xD;
               1. Left bundle branch block (LBBB) and QRS duration of 120-149 ms;&#xD;
&#xD;
               2. Right bundle branch block (RBBB) and QRS ≥ 150 ms.&#xD;
&#xD;
          6. Clinical agreement amongst local investigators that the patient will not be offered&#xD;
             surgical intervention;&#xD;
&#xD;
          7. The primary regurgitant jet, in the opinion of the MitraClip implanting investigator,&#xD;
             can successfully be treated by the MitraClip. Treatment of commissural mitral&#xD;
             regurgitation may be treated at the discretion of the operator. All major jets&#xD;
             contributing the secondary MR will be treated with the MitraClip;&#xD;
&#xD;
          8. Ability to perform a six-minute walk test (6MWT) without substantial physical&#xD;
             limitations and without use of a walker or wheelchair and distance walked in 6 minutes&#xD;
             of ≤ 450m;&#xD;
&#xD;
          9. Ability and willingness to give written informed consent and to comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy less than 12 months due to noncardiac conditions;&#xD;
&#xD;
          2. ACC/AHA Stage D Heart Failure;&#xD;
&#xD;
          3. Left ventricular ejection fraction ≤ 15%;&#xD;
&#xD;
          4. Hypotension (systolic pressure &lt;90 mm Hg) or requirement for inotropic support or&#xD;
             mechanical hemodynamic support;&#xD;
&#xD;
          5. United Network for Organ Sharing (UNOS) status 1 heart transplantation or prior&#xD;
             orthotopic heart transplantation;&#xD;
&#xD;
          6. Untreated clinically significant coronary artery disease requiring revascularization;&#xD;
&#xD;
          7. CABG within prior 30 days;&#xD;
&#xD;
          8. Percutaneous coronary intervention within prior 30 days;&#xD;
&#xD;
          9. Severe Chronic Obstructive Pulmonary Disease (COPD) requiring continuous daytime home&#xD;
             oxygen or chronic oral corticosteroid therapy;&#xD;
&#xD;
         10. Previous surgical mitral valve bioprosthesis, mitral annuloplasty, or transcatheter&#xD;
             mitral valve procedure;&#xD;
&#xD;
         11. Positive pregnancy test, or woman of child bearing potential not using highly&#xD;
             effective methods of contraception;&#xD;
&#xD;
         12. Mitral valve area &lt;4.0 cm2 as assessed by planimetry of the mitral valve;&#xD;
&#xD;
         13. Subjects in whom trans-esophageal echocardiography is contraindicated or high risk;&#xD;
&#xD;
         14. Mitral leaflet anatomy which may preclude MitraClip implantation:&#xD;
&#xD;
               1. Perforated mitral leaflets or clefts, lack of primary or secondary chordal&#xD;
                  support;&#xD;
&#xD;
               2. Severe calcification in the grasping area;&#xD;
&#xD;
               3. Rheumatic valve disease.&#xD;
&#xD;
         15. Previously implanted Cardiac Resynchronization Therapy and Defibrillator (CRT-D)&#xD;
             system;&#xD;
&#xD;
         16. Stroke or transient ischemic event within 30 days before randomization;&#xD;
&#xD;
         17. Modified Rankin Scale &gt;4 disability;&#xD;
&#xD;
         18. Need for emergent or urgent surgery for any reason or any planned cardiac surgery&#xD;
             within the next 12 months;&#xD;
&#xD;
         19. Severe renal impairment defined as an Estimated Glomerular Filtration Rate (eGFR) &lt;30&#xD;
             mL/min/1.73m2 as calculated by the Modification in Diet in Renal Disease (MDRD)&#xD;
             formula;&#xD;
&#xD;
         20. Severe anemia requiring transfusional support or therapy with erythropoietin;&#xD;
&#xD;
         21. Physical evidence of right-sided congestive heart failure with echocardiographic&#xD;
             evidence of moderate or severe right ventricular dysfunction;&#xD;
&#xD;
         22. Aortic valve disease requiring surgery or transcatheter intervention;&#xD;
&#xD;
         23. Significant tricuspid valve disease requiring surgical intervention or very severe&#xD;
             tricuspid regurgitation;&#xD;
&#xD;
         24. Active infection requiring antibiotic therapy;&#xD;
&#xD;
         25. Active endocarditis or active rheumatic heart disease or leaflets degenerated from&#xD;
             rheumatic disease;&#xD;
&#xD;
         26. Echocardiographic evidence of intracardiac mass, thrombus or vegetation;&#xD;
&#xD;
         27. Any condition making it unlikely the patient will be able to complete all protocol&#xD;
             procedures (including compliance with guideline directed medical therapy) and&#xD;
             follow-up visits;&#xD;
&#xD;
         28. Presence of any of the following:&#xD;
&#xD;
               1. Pulmonary artery systolic pressure (PASP) &gt; 70 mm Hg confirmed by right heart&#xD;
                  catheterization;&#xD;
&#xD;
               2. Infiltrative cardiomyopathies.&#xD;
&#xD;
         29. Any other condition(s) that would compromise the safety of the patient as judged by&#xD;
             the site principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Asgar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MitraClip</keyword>
  <keyword>Cardiovascular resynchronization therapy</keyword>
  <keyword>Six minute walk test</keyword>
  <keyword>Mitral regurgitation</keyword>
  <keyword>CRT-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

